Coeliac disease

The Lancet

Volumn 373, Issue 9673, 2009, Pages 1480-1493

  Di Sabatino, Antonio ^a   Corazza, Gino Roberto ^a  

^a FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AMG 714; AT 1001; DACLIZUMAB; FIRATEGRAST; FONTOLIZUMAB; GLUTEN; MLN 02; NATALIZUMAB; OKT 4; PEPTIDE VACCINE; PLACEBO; PROLYL ENDOPEPTIDASE; PROTEIN GLUTAMINE GAMMA GLUTAMYLTRANSFERASE ANTIBODY; RECEPTOR BLOCKING AGENT; RECOMBINANT INTERLEUKIN 10; UNCLASSIFIED DRUG; VISILIZUMAB;

CELIAC DISEASE; CLINICAL FEATURE; COMORBIDITY; DIGESTIVE TRACT ENDOSCOPY; DISEASE COURSE; DRUG MECHANISM; DRUG TOLERABILITY; ENVIRONMENTAL FACTOR; GLUTEN FREE DIET; HISTOPATHOLOGY; HUMAN; INTESTINE BIOPSY; PATHOGENESIS; PREVALENCE; PRIORITY JOURNAL; REVIEW; SEROLOGY; TREATMENT RESPONSE;

EID: 64949090387     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(09)60254-3     Document Type: Review

References (155)

1. Losowsky M.S. A history of coeliac disease. Dig Dis 26 (2008) 112-120
2. Mann N.S., and Leung J.W. Knowledge of some aspects of celiac sprue among professors of gastroenterology. Int Med J 13 (2006) 3-4
3. Mäki M., Mustalahti K., Kokkonen J., et al. Prevalence of celiac disease among children in Finland. N Engl J Med 348 (2003) 2517-2524
4. Tommasini A., Not T., Kiren V., et al. Mass screening for coeliac disease using antihuman transglutaminase antibody assay. Arch Dis Child 89 (2004) 512-515
5. West J., Logan R.F., Hill P.G., et al. Seroprevalence, correlates, and characteristics of undetected coeliac disease in England. Gut 52 (2003) 960-965
6. Fasano A., Berti I., Gerarduzzi T., et al. Prevalence of celiac disease in at-risk and not-at-risk groups in the United States: a large multicenter study. Arch Intern Med 163 (2003) 286-292
7. Hoffenberg E.J., MacKenzie T., Barriga K.J., et al. A prospective study of the incidence of childhood celiac disease. J Pediatr 143 (2003) 308-314
8. Catassi C., Rätsch I.M., Gandolfi L., et al. Why is coeliac disease endemic in the people of the Sahara?. Lancet 354 (1999) 647-648
9. Wieser H. Chemistry of gluten proteins. Food Microbiol 24 (2007) 115-119
10. Kagnoff M.F. Celiac disease: pathogenesis of a model immunogenetic disease. J Clin Invest 117 (2007) 41-49
11. Sturgess R., Day P., Ellis H.J., et al. Wheat peptide challenge in coeliac disease. Lancet 343 (1994) 758-761
12. Maiuri L., Ciacci C., Ricciardelli I., et al. Association between innate response to gliadin and activation of pathogenic T cells in coeliac disease. Lancet 362 (2003) 30-37
13. Molberg Ø., Flaete N.S., Jensen T., et al. Intestinal T-cell responses to high-molecular-weight glutenins in celiac disease. Gastroenterology 125 (2003) 337-344
14. Dewar D.H., Amato M., Ellis H.J., et al. The toxicity of high molecular weight glutenin subunits of wheat to patients with coeliac disease. Eur J Gastroenterol Hepatol 18 (2006) 483-491
15. Wieser H. The precipitating factor in coeliac disease. Baillieres Clin Gastroenterol 9 (1995) 191-207
16. Shan L., Molberg Ø., Parrot I., et al. Structural basis for gluten intolerance in celiac sprue. Science 297 (2002) 2275-2279
17. Corazza G.R., Valentini R.A., Frisoni M., et al. Gliadin immune reactivity is associated with overt and latent enteropathy in relatives of celiac patients. Gastroenterology 103 (1992) 1517-1522
18. Nisticò L., Fagnani C., Coto I., et al. Concordance, disease progression, and heritability of coeliac disease in Italian twins. Gut 55 (2006) 803-808
19. Sollid L.M., Markussen G., Ek J., Gjerde H., Vartdal F., and Thorsby E. Evidence for a primary association of celiac disease to a particular HLA-DQ alpha/beta heterodimer. J Exp Med 169 (1989) 345-350
20. Karell K., Louka A.S., Moodie S.J., et al. HLA types in celiac disease patients not carrying the DQA1*05-DQB1*02 (DQ2) heterodimer: results from the European Genetics Cluster on Celiac Disease. Hum Immunol 64 (2003) 469-477
21. Sollid L.M., and Lie B.A. Celiac disease genetics: current concepts and practical applications. Clin Gastroenterol Hepatol 3 (2005) 843-851
22. Wolters V.M., and Wijmenga C. Genetic background of celiac disease and its clinical implications. Am J Gastroenterol 103 (2008) 190-195
23. Greco L., Corazza G.R., Babron M.C., et al. Genome search in celiac disease. Am J Hum Genet 62 (1998) 669-675
24. Holopainen P., Naluai A.T., Moodie S., et al. Candidate gene region 2q33 in European families with coeliac disease. Tissue Antigens 63 (2004) 212-222
25. Monsuur A.J., de Bakker P.I., Alizadeh B.Z., et al. Myosin IXB variant increases the risk of celiac disease and points toward a primary intestinal barrier defect. Nat Genet 37 (2005) 1341-1344
26. van Heel D.A., Franke L., Hunt K.A., et al. A genome-wide association study for celiac disease identifies risk variants in the region harboring IL2 and IL21. Nat Genet 39 (2007) 827-829
27. Hunt K.A., Zhernakova A., Turner G., et al. Newly identified genetic risk variants for celiac disease related to the immune response. Nat Genet 40 (2008) 395-402
28. Cammarota G., Cuoco L., Cianci R., Pandolfi F., and Gasbarrini G. Onset of coeliac disease during treatment with interferon for chronic hepatitis C. Lancet 356 (2000) 1494-1545
29. Forsberg G., Fahlgren A., Hörstedt P., Hammarström S., Hernell O., and Hammarström M.L. Presence of bacteria and innate immunity of intestinal epithelium in childhood celiac disease. Am J Gastroenterol 99 (2004) 894-904
30. Stene L.C., Honeyman M.C., Hoffenberg E.J., et al. Rotavirus infection frequency and risk of celiac disease autoimmunity in early childhood: a longitudinal study. Am J Gastroenterol 101 (2006) 2333-2340
31. Zanoni G., Navone R., Lunardi C., et al. In celiac disease, a subset of autoantibodies against transglutaminase binds toll-like receptor 4 and induces activation of monocytes. PLoS Med 3 (2006) 1637-1653
32. Ivarsson A., Hernell O., Stenlund H., and Persson L.A. Breast-feeding protects against celiac disease. Am J Clin Nutr 75 (2002) 914-921
33. Norris J.M., Barriga K., Hoffenberg E.J., et al. Risk of celiac disease autoimmunity and timing of gluten introduction in the diet of infants at increased risk of disease. JAMA 293 (2005) 2343-2351
34. Lammers K.M., Lu R., Brownley J., et al. Gliadin induces an increase in intestinal permeability and zonulin release by binding to the chemokine receptor CXCR3. Gastroenterology 135 (2008) 194-204
35. Ciccocioppo R., Finamore A., Ara C., Di Sabatino A., Mengheri E., and Corazza G.R. Altered expression, localization, and phosphorylation of epithelial junctional proteins in celiac disease. Am J Clin Pathol 125 (2006) 502-511
36. Wapenaar M.C., Monsuur A.J., van Bodegraven A.A., et al. Associations with tight junction genes PARD3 and MAGI2 in Dutch patients point to a common barrier defect for coeliac disease and ulcerative colitis. Gut 57 (2008) 463-467
37. Schumann M., Richter J.F., Wedell I., et al. Mechanisms of epithelial translocation of the alpha(2)-gliadin-33mer in coeliac sprue. Gut 57 (2008) 747-754
38. Matysiak-Budnik T., Moura I.C., Arcos-Fajardo M., et al. Secretory IgA mediates retrotranscytosis of intact gliadin peptides via the transferrin receptor in celiac disease. J Exp Med 205 (2008) 143-154
39. Dieterich W., Ehnis T., Bauer M., et al. Identification of tissue transglutaminase as the autoantigen of celiac disease. Nat Med 3 (1997) 797-801
40. van de Wal Y., Kooy Y., van Veelen P., et al. Selective deamidation by tissue transglutaminase strongly enhances gliadin-specific T cell reactivity. J Immunol 161 (1998) 1585-1588
41. Molberg Ø., McAdam S.N., Körner R., et al. Tissue transglutaminase selectively modifies gliadin peptides that are recognized by gut-derived T cells in celiac disease. Nat Med 4 (1998) 713-717
42. Esposito C., Paparo F., Caputo I., et al. Expression and enzymatic activity of small intestinal tissue transglutaminase in celiac disease. Am J Gastroenterol 98 (2003) 1813-1820
43. Kim C.Y., Quarsten H., Bergseng E., Khosla C., and Sollid L.M. Structural basis for HLA-DQ2-mediated presentation of gluten epitopes in celiac disease. Proc Natl Acad Sci USA 101 (2004) 4175-4179
44. Dieterich W., Esslinger B., Trapp D., et al. Cross linking to tissue transglutaminase and collagen favours gliadin toxicity in coeliac disease. Gut 55 (2006) 478-484
45. Qiao S.W., Piper J., Haraldsen G., et al. Tissue transglutaminase-mediated formation and cleavage of histamine-gliadin complexes: biological effects and implications for celiac disease. J Immunol 174 (2005) 1657-1663
46. Vader L.W., Kooy Y., Van Veelen P., et al. The gluten response in children with celiac disease is directed toward multiple gliadin and glutenin peptides. Gastroenterology 122 (2002) 1729-1737
47. Qiao S.W., Bergseng E., Molberg Ø., et al. Antigen presentation to celiac lesion-derived T cells of a 33-mer gliadin peptide naturally formed by gastrointestinal digestion. J Immunol 173 (2004) 1757-1762
48. Nilsen E.M., Jahnsen F.L., Lundin K.E., et al. Gluten induces an intestinal cytokine response strongly dominated by interferon gamma in patients with celiac disease. Gastroenterology 115 (1998) 551-563
49. Monteleone I., Monteleone G., Del Vecchio Blanco G., et al. Regulation of the T helper cell type 1 transcription factor T-bet in coeliac disease mucosa. Gut 53 (2004) 1090-1095
50. Ciccocioppo R., Di Sabatino A., Bauer M., et al. Matrix metalloproteinase pattern in celiac duodenal mucosa. Lab Invest 85 (2005) 397-407
51. Di Sabatino A., Ciccocioppo R., D'Alò S., et al. Intraepithelial and lamina propria lymphocytes show distinct patterns of apoptosis, whereas both the populations are active in Fas-based cytotoxicity in coeliac disease. Gut 49 (2001) 380-386
52. Monteleone G., Pender S.L., Wathen N.C., and MacDonald T.T. Interferon-alpha drives T cell-mediated immunopathology in the intestine. Eur J Immunol 31 (2001) 2247-2255
53. Przemioslo R.T., Kontakou M., Nobili V., and Ciclitira P.J. Raised pro-inflammatory cytokines interleukin 6 and tumour necrosis factor alpha in coeliac disease mucosa detected by immunohistochemistry. Gut 35 (1994) 1398-1403
54. Salvati V.M., MacDonald T.T., Bajaj-Elliott M., et al. Interleukin 18 and associated markers of T helper cell type 1 activity in coeliac disease. Gut 50 (2002) 186-190
55. Fina D., Sarra M., Caruso R., et al. Interleukin 21 contributes to the mucosal T helper cell type 1 response in coeliac disease. Gut 57 (2008) 887-892
56. Forsberg G., Hernell O., Melgar S., Israelsson A., Hammarström S., and Hammarström M.L. Paradoxical coexpression of proinflammatory and down-regulatory cytokines in intestinal T cells in childhood celiac disease. Gastroenterology 123 (2002) 667-678
57. Di Sabatino A., Pickard K.M., Gordon J.N., et al. Evidence for the role of interferon-alfa production by dendritic cells in the Th1 response in celiac disease. Gastroenterology 133 (2007) 1175-1187
58. Mention J.J., Ben Ahmed M., Bègue B., et al. Interleukin 15: a key to disrupted intraepithelial lymphocyte homeostasis and lymphomagenesis in celiac disease. Gastroenterology 125 (2003) 730-745
59. Di Sabatino A., Ciccocioppo R., Cupelli F., et al. Epithelium derived interleukin 15 regulates intraepithelial lymphocyte Th1 cytokine production, cytotoxicity, and survival in coeliac disease. Gut 55 (2006) 469-477
60. Jabri B., De Serre N.P.-M., Cellier C., et al. Selective expansion of intraepithelial lymphocytes expressing the HLA-E-specific natural killer receptor CD94 in celiac disease. Gastroenterology 118 (2000) 867-879
61. Hüe S., Mention J.J., Monteiro R.C., et al. A direct role for NKG2D/MICA interaction in villous atrophy during celiac disease. Immunity 21 (2004) 367-377
62. Benahmed M., Meresse B., Arnulf B., et al. Inhibition of TGF-beta signaling by IL-15: a new role for IL-15 in the loss of immune homeostasis in celiac disease. Gastroenterology 132 (2007) 994-1008
63. Halttunen T., and Maki M. Serum immunoglobulin A from patients with celiac disease inhibits human T84 intestinal crypt epithelial cell differentiation. Gastroenterology 116 (1999) 566-572
64. Barone M.V., Caputo I., Ribecco M.T., et al. Humoral immune response to tissue transglutaminase is related to epithelial cell proliferation in celiac disease. Gastroenterology 132 (2007) 1245-1253
65. Esposito C., Paparo F., Caputo I., et al. Anti-tissue transglutaminase antibodies from coeliac patients inhibit transglutaminase activity both in vitro and in situ. Gut 51 (2002) 177-181
66. Király R., Vecsei Z., Deményi T., Korponay-Szabó I.R., and Fésüs L. Coeliac autoantibodies can enhance transamidating and inhibit GTPase activity of tissue transglutaminase: dependence on reaction environment and enzyme fitness. J Autoimmun 26 (2006) 278-287
67. Corazza G.R., Frisoni M., Treggiari E.A., et al. Subclinical celiac sprue. Increasing occurrence and clues to its diagnosis. J Clin Gastroenterol 16 (1993) 16-21
68. Murray J.A., Van Dyke C., Plevak M.F., Dierkhising R.A., Zinsmeister A.R., and Melton III L.J. Trends in the identification and clinical features of celiac disease in a North American community, 1950-2001. Clin Gastroenterol Hepatol 1 (2003) 19-27
69. Green P.H.R., Stavropoulos S.N., Panagi S.G., et al. Characteristics of adult celiac disease in the USA: results of a national survey. Am J Gastroenterol 96 (2001) 126-131
70. Johnston S.D., Watson R.G., McMillan S.A., Sloan J., and Love A.H. Coeliac disease detected by screening is not silent-simply unrecognized. QJM 91 (1998) 853-860
71. Brar P., Kwon G.Y., Egbuna I.I., et al. Lack of correlation of degree of villous atrophy with severity of clinical presentation of coeliac disease. Dig Liver Dis 39 (2007) 26-29
72. Murray J.A., Rubio-Tapia A., Van Dyke C.T., et al. Mucosal atrophy in celiac disease: extent of involvement, correlation with clinical presentation, and response to treatment. Clin Gastroenterol Hepatol 6 (2008) 186-193
73. Corazza G.R., Di Sario A., Cecchetti L., et al. Bone mass and metabolism in patients with celiac disease. Gastroenterology 109 (1995) 122-128
74. Kemppainen T., Kröger H., Janatuinen E., et al. Osteoporosis in adult patients with celiac disease. Bone 24 (1999) 249-255
75. Mora S., Barera G., Beccio S., et al. A prospective, longitudinal study of the long-term effect of treatment on bone density in children with celiac disease. J Pediatr 139 (2001) 516-521
76. Ludvigsson J.F., Michaelsson K., Ekbom A., and Montgomery S.M. Coeliac disease and the risk of fractures-a general population-based cohort study. Aliment Pharmacol Ther 25 (2007) 273-285
77. Jafri M.R., Nordstrom C.W., Murray J.A., et al. Long-term fracture risk in patients with celiac disease: a population-based study in Olmsted County, Minnesota. Dig Dis Sci 53 (2008) 964-971
78. Lewis N.R., and Scott B.B. Should patients with coeliac disease have their bone mineral density measured?. Eur J Gastroenterol Hepatol 17 (2005) 1065-1070
79. Ventura A., Magazzù G., and Greco L. Duration of exposure to gluten and risk for autoimmune disorders in patients with celiac disease. SIGEP Study Group for Autoimmune Disorders in Celiac Disease. Gastroenterology 117 (1999) 297-303
80. Guidetti C.S., Solerio E., Scaglione N., Aimo G., and Mengozzi G. Duration of gluten exposure in adult coeliac disease does not correlate with the risk for autoimmune disorders. Gut 49 (2001) 502-505
81. Rubio-Tapia A., and Murray J.A. The liver in celiac disease. Hepatology 46 (2007) 1650-1658
82. Bushara K.O. Neurologic presentation of celiac disease. Gastroenterology 128 suppl (2005) 92-97
83. Rostami K., Steegers E.A., Wong W.Y., Braat D.D., and Steegers-Theunissen R.P. Coeliac disease and reproductive disorders: a neglected association. Eur J Obstet Gynecol Reprod Biol 96 (2001) 146-149
84. Mäki M., Holm K., Koskimies S., Hällström O., and Visakorpi J.K. Normal small bowel biopsy followed by coeliac disease. Arch Dis Child 65 (1990) 1137-1141
85. Ferguson A., Arranz E., and O'Mahony S. Clinical and pathological spectrum of coeliac disease-active, silent, latent, potential. Gut 34 (1993) 150-151
86. Collin P., Helin H., Mäki M., Hällström O., and Karvonen A.L. Follow-up of patients positive in reticulin and gliadin antibody tests with normal small-bowel biopsy findings. Scand J Gastroenterol 28 (1993) 595-598
87. Mortimer P.E., Stewart J.S., Norman A.P., and Booth C.C. Follow-up study of coeliac disease. Br Med J 3 (1968) 7-9
88. Matysiak-Budnik T., Malamut G., de Serre N.P., et al. Long-term follow-up of 61 coeliac patients diagnosed in childhood: evolution toward latency is possible on a normal diet. Gut 56 (2007) 1379-1386
89. Fasano A., and Catassi C. Current approaches to diagnosis and treatment of celiac disease: an evolving spectrum. Gastroenterology 120 (2001) 636-651
90. Hin H., Bird G., Fisher P., Mahy N., and Jewell D. Coeliac disease in primary care: case finding study. BMJ 318 (1999) 164-167
91. Korponay-Szabó I.R., Szabados K., Pusztai J., et al. Population screening for coeliac disease in primary care by district nurses using a rapid antibody test: diagnostic accuracy and feasibility study. BMJ 335 (2007) 1244-1247
92. Mulder C.J., and Bartelsman J.F. Case-finding in coeliac disease should be intensified. Best Pract Res Clin Gastroenterol 19 (2005) 479-486
93. Pais W.P., Duerksen D.R., Pettigrew N.M., and Bernstein C.N. How many duodenal biopsy specimens are required to make a diagnosis of celiac disease?. Gastrointest Endosc 67 (2008) 1082-1087
94. Bonamico M., Thanasi E., Mariani P., et al. Duodenal bulb biopsies in celiac disease: a multicenter study. J Pediatr Gastroenterol Nutr 47 (2008) 618-622
95. Oberhuber G., Granditsch G., and Vogelsang H. The histopathology of coeliac disease: time for a standardized report scheme for pathologists. Eur J Gastroenterol Hepatol 11 (1999) 1185-1194
96. Corazza G.R., Villanacci V., Zambelli C., et al. Comparison of the interobserver reproducibility with different histologic criteria used in celiac disease. Clin Gastroenterol Hepatol 5 (2007) 838-843
97. Brown I., Mino-Kenudson M., Deshpande V., and Lauwers G.Y. Intraepithelial lymphocytosis in architecturally preserved proximal small intestinal mucosa: an increasing diagnostic problem with a wide differential diagnosis. Arch Pathol Lab Med 130 (2006) 1020-1025
98. Dewar D.H., and Ciclitira P.J. Clinical features and diagnosis of celiac disease. Gastroenterology 128 suppl (2005) 19-24
99. Hill I.D. What are the sensitivity and specificity of serologic tests for celiac disease? Do sensitivity and specificity vary in different populations?. Gastroenterology 128 suppl (2005) 25-32
100. Carroccio A., Vitale G., Di Prima L., et al. Comparison of anti-transglutaminase ELISAs and an anti-endomysial antibody assay in the diagnosis of celiac disease: a prospective study. Clin Chem 48 (2002) 1546-1550
101. Fabbro E., Rubert L., Quaglia S., et al. Uselessness of anti-actin antibody in celiac disease screening. Clin Chim Acta 390 (2008) 134-137
102. Kaukinen K., Collin P., Laurila K., Kaartinen T., Partanen J., and Mäki M. Resurrection of gliadin antibodies in coeliac disease. Deamidated gliadin peptide antibody test provides additional diagnostic benefit. Scand J Gastroenterol 42 (2007) 1428-1433
103. Cataldo F., Lio D., Marino V., Picarelli A., Ventura A., and Corazza G.R. IgG(1) antiendomysium and IgG antitissue transglutaminase (anti-tTG) antibodies in coeliac patients with selective IgA deficiency. Gut 47 (2000) 366-369
104. Brocchi E., Corazza G.R., Caletti G., Treggiari E.A., Barbara L., and Gasbarrini G. Endoscopic demonstration of loss of duodenal folds in the diagnosis of celiac disease. N Engl J Med 319 (1988) 741-744
105. Jabbari M., Wild G., Goresky C.A., Daly D.S., et al. Scalloped valvulae conniventes: an endoscopic marker of celiac sprue. Gastroenterology 95 (1988) 1518-1522
106. Bardella M.T., Minoli G., Radaelli F., Quatrini M., Bianchi P.A., and Conte D. Reevaluation of duodenal endoscopic markers in the diagnosis of celiac disease. Gastrointest Endosc 51 (2000) 714-716
107. Shah V.H., Rotterdam H., Kotler D.P., Fasano A., and Green P.H. All that scallops is not celiac disease. Gastrointest Endosc 51 (2000) 717-720
108. Cammarota G., Cesaro P., Martino A., et al. High accuracy and cost-effectiveness of a biopsy-avoiding endoscopic approach in diagnosing coeliac disease. Aliment Pharmacol Ther 23 (2006) 61-69
109. Rashtak S., and Murray J.A. Tailored testing for celiac disease. Ann Intern Med 147 (2007) 339-341
110. Catassi C., Fabiani E., Iacono G., et al. A prospective, double-blind, placebo-controlled trial to establish a safe gluten threshold for patients with celiac disease. Am J Clin Nutr 85 (2007) 160-166
111. Kumar P.J., Walker-Smith J., Milla P., Harris G., Colyer J., and Halliday R. The teenage coeliac: follow up study of 102 patients. Arch Dis Child 63 (1988) 916-920
112. O'Leary C., Wieneke P., Healy M., Cronin C., O'Regan P., and Shanahan F. Celiac disease and the transition from childhood to adulthood: a 28-year follow-up. Am J Gastroenterol 99 (2004) 2437-2441
113. Fabiani E., Taccari L.M., Rätsch I.M., Di Giuseppe S., Coppa G.V., and Catassi C. Compliance with gluten-free diet in adolescents with screening-detected celiac disease: a 5-year follow-up study. J Pediatr 136 (2000) 841-843
114. Lee A., and Newman J.M. Celiac diet: its impact on quality of life. J Am Diet Assoc 103 (2003) 1533-1535
115. Vahedi K., Mascart F., Mary J.Y., et al. Reliability of antitransglutaminase antibodies as predictors of gluten-free diet compliance in adult celiac disease. Am J Gastroenterol 98 (2003) 1079-1087
116. Sategna-Guidetti C., Grosso S., Bruno M., and Grosso S.B. Reliability of immunologic markers of celiac sprue in the assessment of mucosal recovery after gluten withdrawal. J Clin Gastroenterol 23 (1996) 101-104
117. Pietzak M.M. Follow-up of patients with celiac disease: achieving compliance with treatment. Gastroenterology 128 suppl (2005) 135-141
118. Kemppainen T., Janatuinen E., Holm K., et al. No observed local immunological response aT cell level after five years of oats in adult coeliac disease. Scand J Gastroenterol 42 (2007) 54-59
119. Lundin K.E., Nilsen E.M., Scott H.G., et al. Oats induced villous atrophy in coeliac disease. Gut 52 (2003) 1649-1652
120. Arentz-Hansen H., Fleckenstein B., Molberg Ø., et al. The molecular basis for oat intolerance in patients with celiac disease. PLoS Med 1 (2004) e1
121. Corrao G., Corazza G.R., Bagnardi V., et al. Mortality in patients with coeliac disease and their relatives: a cohort study. Lancet 358 (2001) 356-361
122. Peters U., Askling J., Gridley G., Ekbom A., and Linet M. Causes of death in patients with celiac disease in a population-based Swedish cohort. Arch Intern Med 163 (2003) 1566-1572
123. West J., Logan R.F., Smith C.J., Hubbard R.B., and Card T.R. Malignancy and mortality in people with coeliac disease: population based cohort study. BMJ 329 (2004) 716-719
124. Solaymani-Dodaran M., West J., and Logan R.F. Long-term mortality in people with celiac disease diagnosed in childhood compared with adulthood: a population-based cohort study. Am J Gastroenterol 102 (2007) 864-870
125. Lewis N.R., Logan R.F., Hubbard R.B., and West J. No increase in risk of fracture, malignancy or mortality in dermatitis herpetiformis: a cohort study. Aliment Pharmacol Ther 27 (2008) 1140-1147
126. Cellier C., Patey N., Mauvieux L., et al. Abnormal intestinal intraepithelial lymphocytes in refractory sprue. Gastroenterology 114 (1998) 471-481
127. Verkarre V., Romana S.P., Cellier C., et al. Recurrent partial trisomy 1q22-q44 in clonal intraepithelial lymphocytes in refractory celiac sprue. Gastroenterology 125 (2003) 40-46
128. Obermann E.C., Diss T.C., Hamoudi R.A., et al. Loss of heterozygosity at chromosome 9p21 is a frequent finding in enteropathy-type T-cell lymphoma. J Pathol 202 (2004) 252-262
129. Cellier C., Delabesse E., Helmer C., et al. Refractory sprue, coeliac disease, and enteropathy-associated T-cell lymphoma. Lancet 356 (2000) 203-208
130. Corazza G.R., Biagi F., Volta U., Andreani M.L., De Franceschi L., and Gasbarrini G. Autoimmune enteropathy and villous atrophy in adults. Lancet 350 (1997) 106-109
131. Fine K.D., Meyer R.L., and Lee E.L. The prevalence and causes of chronic diarrhea in patients with celiac sprue treated with a gluten-free diet. Gastroenterology 112 (1997) 1830-1838
132. Rubio-Tapia A., Kelly D.G., Lahr B.D., Dogan A., Wu T.T., and Murray J.A. Clinical staging and survival in refractory celiac disease: a single center experience. Gastroenterology 136 (2009) 99-107
133. Al-Toma A., Verbeek W.H., Hadithi M., von Blomberg B.M., and Mulder C.J. Survival in refractory coeliac disease and enteropathy-associated T-cell lymphoma: retrospective evaluation of single-centre experience. Gut 56 (2007) 1373-1378
134. Malamut G., Afchain P., Verkarre V., et al. Presentation and long term follow-up of refractory celiac disease: comparison of type I with type II. Gastroenterology 136 (2009) 81-90
135. Ashton-Key M., Diss T.C., Pan L., Du M.Q., and Isaacson P.G. Molecular analysis of T-cell clonality in ulcerative jejunitis and enteropathy-associated T-cell lymphoma. Am J Pathol 151 (1997) 493-498
136. Gale J., Simmonds P.D., Mead G.M., Sweetenham J.W., and Wright D.H. Enteropathy-type intestinal T-cell lymphoma: clinical features and treatment of 31 patients in a single center. J Clin Oncol 18 (2000) 795-803
137. Vivas S., de Morales J.R., Ramos F., and Suárez-Vilela D. Alemtuzumab for refractory celiac disease in a patient at risk for enteropathy-associated T-cell lymphoma. N Engl J Med 354 (2006) 2514-2515
138. Al-Toma A., Goerres M.S., Meijer J.W., et al. Cladribine therapy in refractory celiac disease with aberrant T cells. Clin Gastroenterol Hepatol 4 (2006) 1322-1327
139. Al-Toma A., Visser O.J., van Roessel H.M., et al. Autologous hematopoietic stem cell transplantation in refractory celiac disease with aberrant T cells. Blood 109 (2007) 2243-2249
140. Bishton M.J., and Haynes A.P. Combination chemotherapy followed by autologous stem cell transplant for enteropathy-associated T cell lymphoma. Br J Haematol 136 (2007) 111-113
141. Jantunen E., Juvonen E., Wiklund T., Putkonen M., and Nousiainen T. High-dose therapy supported by autologous stem cell transplantation in patients with enteropathy-associated T-cell lymphoma. Leuk Lymphoma 44 (2003) 2163-2164
142. Corazza G.R., Zoli G., Di Sabatino A., Ciccocioppo R., and Gasbarrini G. A reassessment of splenic hypofunction in celiac disease. Am J Gastroenterol 94 (1999) 391-397
143. Di Sabatino A., Rosado M.M., Miele L., et al. Impairment of splenic IgM-memory but not switched-memory B cells in a patient with celiac disease and splenic atrophy. J Allergy Clin Immunol 120 (2007) 1461-1463
144. Di Sabatino A., Rosado M.M., Cazzola P., et al. Splenic hypofunction and the spectrum of autoimmune and malignant complications in celiac disease. Clin Gastroenterol Hepatol 4 (2006) 179-186
145. Thomas H.J., Wotton C.J., Yeates D., Ahmad T., Jewell D.P., and Goldacre M.J. Pneumococcal infection in patients with coeliac disease. Eur J Gastroenterol Hepatol 20 (2008) 624-628
146. Ludvigsson J.F., Olén O., Bell M., Ekbom A., and Montgomery S.M. Coeliac disease and risk of sepsis. Gut 57 (2008) 1074-1080
147. Vader L.W., Stepniak D.T., Bunnik E.M., et al. Characterization of cereal toxicity for celiac disease patients based on protein homology in grains. Gastroenterology 125 (2003) 1105-1113
148. Molberg Ø., Uhlen A.K., Jensen T., et al. Mapping of gluten T-cell epitopes in the bread wheat ancestors: implications for celiac disease. Gastroenterology 128 (2005) 393-401
149. Spaenij-Dekking L., Kooy-Winkelaar Y., van Veelen P., et al. Natural variation in toxicity of wheat: potential for selection of nontoxic varieties for celiac disease patients. Gastroenterology 129 (2005) 797-806
150. Pyle G.G., Paaso B., Anderson B.E., et al. Effect of pretreatment of food gluten with prolyl endopeptidase on gluten-induced malabsorption in celiac sprue. Clin Gastroenterol Hepatol 3 (2005) 687-694
151. Gass J., Bethune M.T., Siegel M., Spencer A., and Khosla C. Combination enzyme therapy for gastric digestion of dietary gluten in patients with celiac sprue. Gastroenterology 133 (2007) 472-480
152. Mitea C., Havenaar R., Drijfhout J.W., Edens L., Dekking L., and Koning F. Efficient degradation of gluten by a prolyl endoprotease in a gastrointestinal model: implications for coeliac disease. Gut 57 (2008) 25-32
153. Di Cagno R., De Angelis M., Auricchio S., et al. Sourdough bread made from wheat and nontoxic flours and started with selected lactobacilli is tolerated in celiac sprue patients. Appl Environ Microbiol 70 (2004) 1088-1096
154. Gianfrani C., Siciliano R.A., Facchiano A.M., et al. Transamidation of wheat flour inhibits the response to gliadin of intestinal T cells in celiac disease. Gastroenterology 133 (2007) 780-789
155. Bethune M.T., Borda J.T., Ribka E., et al. A non-human primate model for gluten sensitivity. PLoS ONE 3 (2008) e1614